July 2019
Volume 60, Issue 9
ARVO Annual Meeting Abstract  |   July 2019
Artificial Intelligence approaches to enrich clinical trials populations
Author Affiliations & Notes
  • Ursula Schmidt-Erfurth
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships   Ursula Schmidt-Erfurth, Alcon (C), Boehringer (C), Genentech (C), Novartis (C), Roche (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 993. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ursula Schmidt-Erfurth; Artificial Intelligence approaches to enrich clinical trials populations. Invest. Ophthalmol. Vis. Sci. 2019;60(9):993. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : Clinical trials particularly in slowly progressive disease or pathologies with a wide variability represent a major challenge for investigators as well as sponsors. Artificial intelligence (AI) has the capacity to identify risk profiles and prognostic biomarkers which can be used to characterize study populations in a reliable and stringent manner a priori. Multimodal imaging including high-resolution three-dimensional OCT offers a wealth of morphological features which can be exploited comprehensively using deep learning. Such analyses have been successfully applied to understand the risk of conversion from early to advanced age-related macular degeneration (AMD), prognostic outcomes in neovascular AMD and diabetic macular edema (DME) as well as geographic atrophy (GA). AI provides defined and quantified markers reflecting disease activity beyond classic clinical features such as drusen volume and hyperreflective foci thereby largely expanding the conventional spectrum of pathognomonic markers. This quality enables the search for novel therapeutic targets and furthers insights into the pathophysiology of disease.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.